News Roche's Tecentriq hits trouble with NICE in bladder cancer Cancer Drugs Fund could cover costs in first line use.
News AZ immunotherapy gets FDA boost in early lung cancer Imfinzi given Breakthrough Therapy designation from the FDA.
News Europe recommends Tecentriq in bladder cancer, but efficacy ... The European Union’s CHMP committee recommended 11 medicines on Friday, including five orphan drugs.
News The week that turned the cancer immunotherapy market on its ... Contrasting fortunes for Roche and AZ in a week of drama.
News Drama as Roche's Tecentriq fails in key bladder cancer trial Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.